sanofi

28th July 2026

The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 544250	The Secretary National Stock Exchange of India Limited C-1, Block G, Exchange Plaza, Bandra-Kurla Complex, Bandra East, Mumbai - 400 051 Symbol: SANOFICONR

Sub.: Outcome of Board Meeting held on Tuesday, 28th July 2026

Dear Sir/Madam,

We refer to our letter dated 22nd July 2026 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Tuesday, 28th July 2026, *inter-alia* considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026.

Further, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we enclose herewith a copy of the Unaudited Financial Results for the quarter and half year ended 30th June 2026, as approved at the aforesaid meeting, along with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company. In this regard, please also find enclosed the accompanying press release.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI Listing Regulations. The aforesaid financial results will also be available on the Company's website at https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results

The meeting of Board of Directors commenced at 4:00 p.m. and concluded at 6:00 p.m.

Kindly take the above information on record.

Thanking you.

Yours faithfully,
For **Sanofi Consumer Healthcare India Limited**

Nikunjkumar Jaysukhlal Savaliya

Digitally signed by Nikunjkumar Jaysukhlal Savaliya
Date: 2026.07.28 19:36:29 +05'30'

Nikunjkumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

Review Report

To
The Board of Directors
Sanofi Consumer Healthcare India Limited
Unit 1104, 11th Floor, Godrej Two,
Pirojshanagar, Eastern Express Highway,
Vikhroli East, Mumbai 400079.
Maharashtra, India

1. We have reviewed the unaudited financial results of Sanofi Consumer Healthcare India Limited (the "Company") for the quarter ended June 30, 2026 and the year to date results for the period January 1, 2026 to June 30, 2026, the Unaudited Statement of Assets and Liabilities as on that date and the Unaudited Statement of Cash Flows for the half-year ended on that date which are included in the accompanying 'Statement of unaudited financial results for the quarter and half year ended June 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. (a) The financial results of the Company for the quarters ended March 31, 2026 and June 30, 2025 and the year to date results for the period January 1, 2025 to June 30, 2025 were reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their reports dated April 28, 2026 and August 4, 2025, respectively.

   (b) The financial statements of the Company for the year ended December 31, 2025 were also audited by the another firm of chartered accountants, who issued an unmodified opinion vide their report dated February 25, 2026.

Our conclusion is not modified in respect of these matters.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.07.28 19:22:22 +05'30'

Arunkumar Ramdas
Partner
Membership Number: 112433

UDIN: 26112433JOQKAW3141
Mumbai
July 28, 2026

Sanofi Consumer Healthcare India Limited
Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079
Corporate Identity Number: L21002MH2023PLC402652
Tel no: (91-22) 45288555
Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED JUNE 30, 2026

₹ in Million

Particulars	Quarter ended 30.06.2026 (Unaudited)	Quarter ended 31.03.2026 (Unaudited)	Quarter ended 30.06.2025 (Unaudited)	Half year ended 30.06.2026 (Unaudited)	Half year ended 30.06.2025 (Unaudited)	Year ended 31.12.2025 (Audited)
1. Revenue from Operations (Refer Note 8)	2,357	2,292	2,209	4,649	3,935	8,784
2. Other Income	63	56	56	119	108	184
3. Total Income (1+2)	2,420	2,348	2,265	4,768	4,043	8,968
4. Expenses						
(a) Cost of Materials Consumed	475	402	554	877	743	1,607
(b) Purchases of stock in trade	160	181	46	341	381	702
(c) Changes in Inventories of stock in trade and finished goods	(72)	(21)	12	(93)	(124)	(8)
(d) Employee benefits expense (Refer Note 4)	313	331	320	644	616	1,288
(e) Finance costs	4	5	5	9	9	20
(f) Depreciation and amortisation expense	33	32	30	65	50	117
(g) Other expenses	588	511	575	1,099	977	2,105
Total Expenses	1,501	1,441	1,542	2,942	2,652	5,831
5. Profit before exceptional item and tax (3-4)	919	907	723	1,826	1,391	3,137
6. Exceptional item (Refer Note 5)	-	-	66	-	66	66
7. Profit before tax (5+6)	919	907	789	1,826	1,457	3,203
8. Tax expense						
Current Tax	234	241	184	475	354	820
Deferred Tax	(3)	(12)	(2)	(15)	(4)	(18)
9. Profit for the period /year (7-8)	688	678	607	1,366	1,107	2,401
10. Other comprehensive income (OCI)						
Items that will not be reclassified to the statement of profit and loss						
- Remeasurements of post-employment benefit obligations	-	-	-	-	-	(19)
- Income tax impact relating to these items	-	-	-	-	-	5
11. Total comprehensive income for the period/year (9+10)	688	678	607	1,366	1,107	2,387
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	3,610
14. Basic and diluted earnings per share (not annualised) (in ₹)	29.87	29.44	26.36	59.31	48.07	104.27

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated July 28, 2026.

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.07.28 19:23:29 +05'30'

Himanshu Bakshi

Digitally signed by Himanshu Bakshi
Date: 2026.07.28 18:46:29 +05'30'

Sanofi Consumer Healthcare India Limited

UNAUDITED STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

Particulars	**As at June 30, 2026 (Unaudited)**	**As at December 31, 2025 (Audited)**
ASSETS		
Non-current assets		
Property, plant and equipment	122	138
Capital work in progress	-	*
Right-of-use assets	173	213
Intangible assets	3	8
Financial assets		
Other financial assets	32	32
Income tax assets (net)	-	51
Deferred tax assets (net)	100	85
Total non-current assets	**430**	**527**
Current assets		
Inventories	937	619
Financial assets		
(i) Trade receivables	498	296
(ii) Cash and cash equivalents	4,902	3,748
(iii) Bank Balances other than (ii) above	4	4
(iv) Loans	-	1
(v) Other financial assets	17	-
Other current assets	276	275
Total current assets	**6,634**	**4,943**
TOTAL ASSETS	**7,064**	**5,470**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	230	230
Other equity		
Reserve and Surplus	3,249	3,610
Total equity	**3,479**	**3,840**
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Lease liabilities	128	171
Employee benefit obligations	186	175
Total non-current liabilities	**314**	**346**
Current liabilities		
Financial liabilities		
(i) Lease liabilities	80	77
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	104	52
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	906	744
(iii) Other financial liabilities	1,772	211
Employee Benefit Obligations	58	58
Provisions	114	112
Current tax liabilities (net)	68	-
Other current liabilities	169	30
Total current liabilities	**3,271**	**1,284**
Total liabilities	**3,585**	**1,630**
TOTAL EQUITY AND LIABILITIES	**7,064**	**5,470**

*denotes figure less than a million

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with their LODR Regulations review report dated July 28, 2026.

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.07.28 19:23:52 +05'30'

Himanshu Bakshi

Digitally signed by Himanshu Bakshi
Date: 2026.07.28 18:47:25 +05'30'

Sanofi Consumer Healthcare India Limited

UNAUDITED STATEMENT OF CASH FLOWS FOR HALF YEAR ENDED JUNE 30, 2026

₹ in Million

Particulars	Half year ended June 30, 2026 (Unaudited)	Half year ended June 30, 2025 (Unaudited)
Cash flows from Operating activities	**1,826**	**1,457**
Profit before tax		
Adjustment for :		
Depreciation and amortisation expense	65	50
Unrealised exchange loss/(gain)	3	(21)
Finance costs	9	9
Interest income on Fixed Deposit	(109)	(83)
Interest on Income tax refund	(4)	-
Provision for bad and doubtful debts (net)	(3)	3
Write-off of property, plant and equipment (net)	2	-
Operating profit before working capital changes	**1,789**	**1,415**
Adjustments for (increase) / decrease in operating assets		
Non-current financial assets	-	(1)
Inventories	(318)	(371)
Trade receivables	(205)	(289)
Current financial assets	(17)	27
Loans	1	-
Other current assets	(1)	(198)
Adjustments for increase / (decrease) in operating liabilities		
Employee benefit obligations	11	(2)
Trade payables	217	183
Other financial Liablities	(26)	(50)
Other current liabilities & provisions	1	(185)
Cash generated from operations	**1,452**	**529**
Taxes paid (net of refunds)	(356)	(350)
Net Cash inflow from Operating activities (A)	**1,096**	**179**
Cash flows from Investing activities		
Interest received from Fixed Deposit	109	83
Interest on Income tax refund	4	-
Purchase of property, plant and equipment including Capital work-in-progress	(8)	(69)
Net cash inflow from Investing activities (B)	**105**	**14**
Cash flows from financing activities		
Principal elements of lease payments	(38)	(22)
Interest paid on lease	(9)	(9)
Dividend paid	-	(1,267)
Net cash used in financing activities (C)	**(47)**	**(1,298)**
Net increase / (decrease) in cash and cash equivalents (A+B+C)	**1,154**	**(1,105)**
Cash and Cash Equivalents at the beginning of the period	3,748	3,269
Cash and Cash Equivalents at the end of the period	**4,902**	**2,164**
Non- cash financing and investing activities		
Acquisition of Right-of-use assets	4	103

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with their LODR Regulations review report dated July 28, 2026.

ARUNKUMAR RAMDAS

Digitally signed by ARUNKUMAR RAMDAS
Date: 2026.07.28 19:24:16 +05'30'

Himanshu Bakshi

Digitally signed by Himanshu Bakshi
Date: 2026.07.28 18:49:40 +05'30'

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on July 28, 2026. The statutory auditors have carried out a limited review of the above results for the quarter and half year ended June 30, 2026.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.

3. In 2024, the Company had voluntarily decided to recall Combiflam Suspension, Allegra Suspension and Depura Kids from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the Company had successfully relaunched Combiflam Suspension during the quarter ended June 2025 and Allegra Suspension and Depura Kids in quarter ended September 2025. Consequently, there were no sales of Combiflam Suspension, Allegra Suspension and Depura Kids in quarter ended March 31, 2025 and of Allegra Suspension and Depura Kids in quarter ended June 30, 2025. Hence, the results are not fully comparable with the corresponding quarter and half year of the previous year as the product recall and subsequent relaunches had an impact on the domestic business.

4. The Government of India notified four New Labour Codes effective November 21, 2025 replacing the existing 29 Labour laws. The Ministry of Labour & Employment has also issued draft Central Rules and FAQS to help assess the financial impact of these changes. The Company has ascertained its estimated obligations under the New Labour Codes based on actuarial valuation, best estimates and consistent with guidance provided by the Institute of Chartered Accountants of India.

   The Company had recognised an incremental financial impact of ₹ 24 million as past service cost resulting in an increase in gratuity liability and compensated absences, arising due to change in the definition of wages, under Employee Benefits Expense in year ended December 31, 2025. The Company will continue to monitor the finalization of the relevant Central and State Rules and will evaluate impact, if any, on the measurement of employee benefits and will provide appropriate accounting treatment in the period in which such rules or related clarifications are notified.

5. Exceptional item for quarter ended June 30, 2025 and year ended December 31, 2025 pertains to the reversal of ₹66 million related to demerger provisions made in 2024.

6. The Company has a single business segment namely ‘Pharmaceutical Business’. Therefore, disclosure relating to segments under Ind AS 108 is not applicable and accordingly not made.

7. The Company does not have any subsidiary, associates or joint ventures as on June 30, 2026.

8. Revenue from operations includes sales of products and service income. Sales of products is as under:

₹ in Million

Particulars	**Quarter ended (Unaudited)**			**Half Year Ended (Unaudited)**		**Year ended (Audited)**
	30.06.2026	**31.03.2026**	**30.06.2025**	**30.06.2026**	**30.06.2025**	**31.12.2025**
Sales of Product	2,132	2,063	2,023	4,196	3,610	8,045

ARUNKUMA R RAMDAS Digitally signed by ARUNKUMAR RAMDAS Date: 2026.07.28 19:24:49 +05'30'

Place: Mumbai
July 28, 2026

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated July 28, 2026.

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu Bakshi
Managing Director

Himansh u Bakshi Digitally signed by Himanshu Bakshi Date: 2026.07.28 18:52:06 +05'30'

DIN: 08188412

Press Release

Sanofi Consumer Healthcare India Limited reports

Q2’26 Revenue at ₹2,357 MN, Net Profit at ₹919 MN

Highlights for the Quarter Y-O-Y:

- Revenue at ₹2,357 million, a growth of 7%
- Domestic Sales grew by 12%; aided by relaunch
- Export Sales declined by 9%; on a high base
- Profit Before Tax up by 16%

Highlights for the Half Year

- Revenue from Operations at ₹4,649 million, a growth of 18%
- Domestic Sales grew by 14%; aided by relaunch
- Export Sales grew by 27%; on a low base,
- Profit Before Tax up by 25%

Mumbai, 28 July 2026: Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) releases its financial results for the second quarter and half year ending 2026, demonstrating profitable growth across key business segments. Revenue growth for the quarter stood at 7% year-on-year with Domestic sales growing by 12%, aided by relaunch. Profit Before tax (PBT) for Q2 ‘26 reached ₹919 million, an increase of 16% on a year-on-year basis.

Commenting on the Q2’26 results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited,** said, “*Our performance this quarter reflects the disciplined execution on all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in the strength of our strategy.*”

About Sanofi Consumer Healthcare India Limited.

Sanofi Consumer Healthcare India Limited (SCHIL) emerged as a distinct legal entity following its demerger from Sanofi India Limited on 1st June 2024. SCHIL now operates independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India's consumer healthcare market. Leveraging its global experience in consumer healthcare, SCHIL aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care and Multivitamins. SCHIL’s key brands include Allegra®, DePURA®, Avil® and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

Contacts for Media Relations:
Clayton Dsouza | +91 9930011602 | claytond@avianwe.com
Shrutika Sukhi | +91 9167971057 | shrutikas@avianwe.com